CannaPharmaRx Inc
OTC:CPMD

Watchlist Manager
CannaPharmaRx Inc Logo
CannaPharmaRx Inc
OTC:CPMD
Watchlist
Price: 0.003 USD Market Closed
Market Cap: 2m USD

Relative Value

CPMD doesn't have a meaningful market cap.

The Relative Value of one CPMD stock under the Base Case scenario is 0.001 USD. Compared to the current market price of 0.003 USD, CannaPharmaRx Inc is Overvalued by 68%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CPMD Relative Value
Base Case
0.001 USD
Overvaluation 68%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
20
vs Industry
18
Median 3Y
0
Median 5Y
0
Industry
2.6
vs History
15
vs Industry
45
Median 3Y
-0.2
Median 5Y
-0.3
Industry
22.2
vs History
vs Industry
49
Median 3Y
-1.8
Median 5Y
-1.9
Industry
17.2
vs History
vs Industry
22
Median 3Y
-3.7
Median 5Y
-3.7
Industry
23.7
vs History
vs Industry
Median 3Y
-0.2
Median 5Y
-0.2
Industry
2.2
vs History
20
vs Industry
6
Median 3Y
0
Median 5Y
0
Industry
2.8
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.4
vs History
vs Industry
Median 3Y
-7.9
Median 5Y
-7
Industry
13.3
vs History
vs Industry
Median 3Y
-7.2
Median 5Y
-6.8
Industry
16.8
vs History
vs Industry
41
Median 3Y
-8
Median 5Y
-9.1
Industry
15.6
vs History
vs Industry
31
Median 3Y
-7.9
Median 5Y
-8.9
Industry
18.1
vs History
39
vs Industry
18
Median 3Y
4.1
Median 5Y
3.8
Industry
2

Multiples Across Competitors

CPMD Competitors Multiples
CannaPharmaRx Inc Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
CA
CannaPharmaRx Inc
OTC:CPMD
2m USD 5.8 1.4 -11 -11.1
US
Eli Lilly and Co
NYSE:LLY
735.9B USD 15 66.3 35.6 38.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
404B USD 4.5 17.8 13.6 17.9
DK
Novo Nordisk A/S
CSE:NOVO B
1.9T DKK 6.2 18 12.5 14.3
CH
Roche Holding AG
SIX:ROG
202.1B CHF 3.3 24.4 9.2 10.8
CH
Novartis AG
SIX:NOVN
178.4B CHF 4.1 16.5 9.9 13.2
UK
AstraZeneca PLC
LSE:AZN
160.5B GBP 3.9 27.9 130.7 197
US
Merck & Co Inc
NYSE:MRK
205.3B USD 3.2 11.8 8.7 10.6
IE
Endo International PLC
LSE:0Y5F
183.8B USD 79.3 -62.9 292.4 733.2
US
Pfizer Inc
NYSE:PFE
142.9B USD 2.3 18.1 7.7 10.9
P/E Multiple
Earnings Growth PEG
CA
CannaPharmaRx Inc
OTC:CPMD
Average P/E: 22.5
1.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
66.3
49%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.8
27%
0.7
DK
Novo Nordisk A/S
CSE:NOVO B
18
18%
1
CH
Roche Holding AG
SIX:ROG
24.4
32%
0.8
CH
Novartis AG
SIX:NOVN
16.5
17%
1
UK
AstraZeneca PLC
LSE:AZN
27.9
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.8
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -62.9 N/A N/A
US
Pfizer Inc
NYSE:PFE
18.1
30%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CA
CannaPharmaRx Inc
OTC:CPMD
Average EV/EBITDA: 436.7
Negative Multiple: -11
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
35.6
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
13.6
7%
1.9
DK
Novo Nordisk A/S
CSE:NOVO B
12.5
13%
1
CH
Roche Holding AG
SIX:ROG
9.2
5%
1.8
CH
Novartis AG
SIX:NOVN
9.9
5%
2
UK
AstraZeneca PLC
LSE:AZN
130.7
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.7
8%
1.1
IE
E
Endo International PLC
LSE:0Y5F
292.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.7
2%
3.9
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CA
CannaPharmaRx Inc
OTC:CPMD
Average EV/EBIT: 1 874.9
Negative Multiple: -11.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38.9
32%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
17.9
13%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
14.3
14%
1
CH
Roche Holding AG
SIX:ROG
10.8
6%
1.8
CH
Novartis AG
SIX:NOVN
13.2
10%
1.3
UK
AstraZeneca PLC
LSE:AZN
197
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.6
11%
1
IE
E
Endo International PLC
LSE:0Y5F
733.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.9
10%
1.1